Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
Welcome,
Profile
Billing
Logout
12 Diseases
138 Trials
138 Trials
3994 News
«
1
2
...
28
29
30
31
32
33
34
35
36
37
38
39
40
||
||||||||
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
Combination therapy:
SUSTAIN
(clinicaltrials.gov) - Dec 7, 2014
P3
, N=390, Recruiting,
Sponsor: Novo Nordisk A/S
||||||||||
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
Clinical:
Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects
(clinicaltrials.gov) - Dec 5, 2014
P1
, N=28, Active, not recruiting,
Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting
||||||||||
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
Clinical:
Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo
(clinicaltrials.gov) - Nov 3, 2014
P1
, N=30, Active, not recruiting,
Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Trial primary completion date: May 2015 --> Jan 2015
||||||||||
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
Clinical:
A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects
(clinicaltrials.gov) - Oct 23, 2014
P1
, N=44, Completed,
Sponsor: Novo Nordisk A/S
Trial primary completion date: May 2015 --> Jan 2015 Active, not recruiting --> Completed
|
|||||||||
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
Monotherapy:
SUSTAIN: A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes
(clinicaltrials.gov) - Oct 4, 2014
P3
, N=306, Recruiting,
Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
||
||||||||
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
Monotherapy:
SUSTAIN: A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes
(clinicaltrials.gov) - Oct 2, 2014
P3
, N=306, Not yet recruiting,
Sponsor: Novo Nordisk A/S
||||||||||
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
Clinical:
Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects
(clinicaltrials.gov) - Sep 30, 2014
P1
, N=28, Recruiting,
Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
||||||||||
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
Clinical:
A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes
(clinicaltrials.gov) - Sep 28, 2014
P1
, N=38, Active, not recruiting,
Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
||||||||||
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
Clinical:
Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects
(clinicaltrials.gov) - Sep 19, 2014
P1
, N=28, Not yet recruiting,
Sponsor: Novo Nordisk A/S
||||||||||
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
Clinical:
A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects
(clinicaltrials.gov) - Sep 4, 2014
P1
, N=44, Active, not recruiting,
Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2015 --> Oct 2014
|
|||||||||
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
Clinical:
SUSTAIN™1: Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes
(clinicaltrials.gov) - Aug 25, 2014
P3
, N=390, Active, not recruiting,
Sponsor: Novo Nordisk A/S
Trial primary completion date: Feb 2015 --> Oct 2014 Recruiting --> Active, not recruiting
||||||||||
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
Clinical:
A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes
(clinicaltrials.gov) - Aug 15, 2014
P1
, N=86, Recruiting,
Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
||||||||||
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
Clinical:
A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes
(clinicaltrials.gov) - Aug 8, 2014
P1
, N=86, Not yet recruiting,
Sponsor: Novo Nordisk A/S
|
|||||||||
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
Clinical:
SUSTAIN™ 2: Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes
(clinicaltrials.gov) - Aug 7, 2014
P3
, N=1200, Active, not recruiting,
Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
|
|||||||||
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
Clinical:
SUSTAIN 4: Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes
(clinicaltrials.gov) - Aug 6, 2014
P3
, N=1047, Recruiting,
Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
|
|||||||||
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
Combination therapy, Monotherapy:
A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes
(clinicaltrials.gov) - Aug 5, 2014
P3
, N=595, Recruiting,
Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
||
||||||||
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
Combination therapy, Monotherapy:
A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes
(clinicaltrials.gov) - Aug 4, 2014
P3
, N=595, Not yet recruiting,
Sponsor: Novo Nordisk A/S
||||||||||
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
Clinical:
Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo
(clinicaltrials.gov) - Jul 4, 2014
P1
, N=30, Active, not recruiting,
Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
||||||||||
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
Clinical:
A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects
(clinicaltrials.gov) - Jun 27, 2014
P1
, N=44, Active, not recruiting,
Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
||||||||||
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
Clinical:
A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes
(clinicaltrials.gov) - May 22, 2014
P1
, N=38, Recruiting,
Sponsor: Novo Nordisk A/S
||||||||||
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
Clinical:
A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects
(clinicaltrials.gov) - May 21, 2014
P1
, N=44, Recruiting,
Sponsor: Novo Nordisk A/S
||
||||||||
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
Clinical:
SUSTAIN 4: Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes
(clinicaltrials.gov) - Apr 23, 2014
P3
, N=1047, Not yet recruiting,
Sponsor: Novo Nordisk A/S
||||||||||
Rybelsus
(semaglutide oral) /
Novo Nordisk
,
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
Enrollment closed:
Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes
(clinicaltrials.gov) - Apr 23, 2014
P2
, N=603, Active, not recruiting,
Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
|
|||||||||
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
Clinical:
SUSTAIN™ 3: Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes
(clinicaltrials.gov) - Apr 22, 2014
P3
, N=798, Active, not recruiting,
Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
||||||||||
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
Clinical:
Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo
(clinicaltrials.gov) - Mar 9, 2014
P1
, N=30, Recruiting,
Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
||||||||||
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
Clinical:
Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo
(clinicaltrials.gov) - Mar 4, 2014
P1
, N=30, Recruiting,
Sponsor: Novo Nordisk A/S
|
|||||||||
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
Clinical:
SUSTAIN™1: Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes
(clinicaltrials.gov) - Feb 3, 2014
P3
, N=390, Recruiting,
Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
||
||||||||
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
Clinical:
SUSTAIN™1: Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes
(clinicaltrials.gov) - Feb 2, 2014
P3
, N=390, Recruiting,
Sponsor: Novo Nordisk A/S
|||||
|||||
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
Clinical:
SUSTAIN™ 6: Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes
(clinicaltrials.gov) - Dec 10, 2013
P3
, N=3260, Active, not recruiting,
Sponsor: Novo Nordisk
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
||||||
||||
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
Clinical:
SUSTAIN™ 2: Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes
(clinicaltrials.gov) - Dec 3, 2013
P3
, N=1200, Recruiting,
Sponsor: Novo Nordisk
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
||||||||||
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
Clinical:
SUSTAIN™ 2: Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes
(clinicaltrials.gov) - Aug 26, 2013
P3
, N=1200, Recruiting,
Sponsor: Novo Nordisk
|
|||||||||
Rybelsus
(semaglutide oral) /
Novo Nordisk
,
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
New P2 trial:
Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes
(clinicaltrials.gov) - Aug 13, 2013
P2
, N=603, Active, not recruiting,
Sponsor: Novo Nordisk A/S
||
||||||||
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
Clinical:
SUSTAIN™ 3: Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes
(clinicaltrials.gov) - Jun 20, 2013
P3
, N=798, Active, not recruiting,
Sponsor: Novo Nordisk A/S
||||||||||
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
Clinical:
SUSTAIN™ 6: Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes
(clinicaltrials.gov) - Oct 31, 2012
P3
, N=3260, Active, not recruiting,
Sponsor: Novo Nordisk
|
|||||||||
Ozempic
(semaglutide SC once-weekly) /
Novo Nordisk
Clinical:
Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 Diabetes
(clinicaltrials.gov) - Jan 19, 2012
P1
, N=43, Completed,
Sponsor: Novo Nordisk
Not yet recruiting --> Recruiting Active, not recruiting --> Completed